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Abstract
Background Electrical cardioversion (ECV) is a procedure in which a direct current electric shock is used to quickly and 
effectively restore the normal sinus rhythm. Appropriate anticoagulation reduces the risk of embolic events during and after 
ECV. The aim of this study was to estimate the cost-effectiveness of rivaroxaban compared with vitamin K oral antagonists 
(VKAs) in patients with atrial fibrillation undergoing elective ECV in the Netherlands.
Methods and results A static transmission model over a 1-year time horizon was developed to compare rivaroxaban with 
VKAs in terms of clinical outcomes, health effects (quality-adjusted life years; QALYs), and costs. Cost-effectiveness was 
assessed from a societal and health care payer perspective at a willingness-to-pay level of €20,000 per QALY gained. The 
use of rivaroxaban as an anticoagulant in patients with atrial fibrillation scheduled for ECV would lead to a health gain of 
0.23 QALYs per patient and would cost €1.83 per patient from the societal perspective, resulting in an incremental cost-
effectiveness ratio of €7.92 per QALY gained. The probability of rivaroxaban being cost-saving compared with VKAs was 
49.6% from this perspective. From the health care payer perspective, the incremental cost would be €509 per patient with 
a health gain of 0.23 QALYs per patient, resulting in an incremental cost-effectiveness ratio of €2198 per QALY gained.
Conclusions The use of rivaroxaban in elective ECV is a cost-effective alternative to the use of VKAs. Rivaroxaban has a 
50% probability of being cost-saving compared with VKAs and would increase a patient’s quality of life when non-health 
care costs such as productivity loss and informal care costs are taken into account.
Keywords Cardioversion · Oral anticoagulation · Rivaroxaban · Vitamin K oral antagonists · Health economic evaluation
JEL Classification I10 Health, General · C63 Computational Techniques, Simulation Modeling · D61 Allocative Efficiency, 
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Introduction
Atrial fibrillation (AF) is a cardiac arrhythmia with a preva-
lence of 5.5% in the population older than 55 years in the 
Netherlands, and prevalence increases with age [1, 2]. In 
the Netherlands, AF is newly diagnosed in around 45,000 
patients every year, and the total cost for all AF patients 
(including hospitalization, in-hospital procedures, and 
pharmacotherapeutic management) has been estimated at 
€600 million per year [2]. Patients with AF have a fivefold 
increased risk of stroke and increased chance of developing 
systemic embolism (SE) [3]. Anticoagulants can be used to 
reduce the thromboembolic risk. Symptomatic AF patients 
have a lower quality of life compared with nonsymptomatic 
AF patients. Symptoms can be very limiting for a patient, 
ranging from “troubled by symptoms but normal daily activ-
ity not affected” up to the point where normal daily activity 
is discontinued [4]. Severe and disabling AF, which accounts 
for around 30% of all AF patients, can have a great economic 
impact because of a decrease in general health and subse-
quent loss of work productivity [5]. The thromboembolic 
risk appears not to be affected by the symptomatic status of 
an AF patient, and the clinical status should therefore not 
determine the stroke prevention approach [6]. The symptoms 
nonetheless do determine the eligibility for cardioversion. 
In early stages of AF, symptomatic patients can undergo 
electrical cardioversion (ECV). ECV is a procedure in which 
a direct current electric shock is used to quickly and effec-
tively restore the normal sinus rhythm [7, 8]. The risk of 
SE and stroke is increased around the time of ECV, mainly 
because of a temporary stasis of the blood. Appropriate 
anticoagulation reduces the risk of these embolic events 
during and after the ECV procedure, but it increases the 
risk of bleeding [9]. An elective ECV strategy with at least 
3 weeks of anticoagulant treatment is chosen if AF is pre-
sent for more than 48 h. In elective ECV, the patient has to 
receive adequate anticoagulation for at least 3 weeks before 
and at least 4 weeks after the procedure [7]. Patients at risk 
of stroke are eligible for life-long anticoagulation and can 
be identified by the  CHA2DS2-VASc score [10]. Nowadays, 
in patients with AF there is a preference toward prescrib-
ing a non-vitamin K antagonist oral anticoagulant (NOAC) 
over a vitamin K oral antagonist (VKA) [8, 11]. VKAs are 
relatively inexpensive drugs but have an unpredictable thera-
peutic response. For this reason, strict monitoring of the 
patient’s blood coagulation by means of the international 
normalized ratio (INR) is required. The NOAC rivaroxaban 
is a direct factor Xa oral antagonist, indicated for prevention 
of stroke and SE in nonvalvular AF patients. Clinical trials 
have shown similar effects for rivaroxaban and VKAs in 
the prevention of stroke and SE in AF patients, and also in 
those undergoing ECV as shown in the X-VerT trial [12, 13]. 
Rivaroxaban has a more predictable pharmacokinetic and 
pharmacodynamic profile and has fewer drug–drug inter-
actions, and INR measurement is not required [12]. High 
rates of inadequate anticoagulation, up to 50%, have been 
an extensive problem with VKA use and the most frequent 
reason to postpone ECV [14–16]. Because of the rapid onset 
of anticoagulation with rivaroxaban, cardioversion can be 
performed significantly earlier and inadequate anticoagula-
tion before cardioversion is less frequent [13]. In a post hoc 
budget-impact analysis of the X-VeRT trial, it was estimated 
that the use of rivaroxaban compared with a VKA resulted in 
a cost saving of £421 per patient in the UK setting and €360 
per patient in the Italian setting [14]. This budget-impact 
analysis did not include AF-related event costs and non-
health care costs. An extensive cost-effectiveness analysis 
including the total budget impact of all costs relevant for 
elective ECV with rivaroxaban has not yet been published. 
The aim of this study was to estimate the cost-effectiveness 
of rivaroxaban compared with a VKA in patients with AF 
undergoing elective ECV in the Netherlands.
Methods
Overview
In this health economic evaluation, we used a static transmis-
sion model over a 1-year time horizon to compare rivaroxaban 
with VKAs in elective ECV in terms of clinical outcomes, 
health effects, and costs. The clinical outcomes were AF-
related events, such as stroke and hemorrhage. Costs were 
assessed from a societal perspective, also accounting for non-
health care costs due to productivity losses and informal care, 
which is in line with the Dutch pharmacoeconomic guidelines 
[17]. The final outcomes were incremental costs and quality-
adjusted life years (QALYs). Cumulative health effects, direct 
costs, and indirect costs were determined for elective ECV 
with rivaroxaban and VKAs. The incremental cost-effective-
ness ratio (ICER) of rivaroxaban compared with VKAs was 
calculated by division of the difference in costs by the differ-
ence in QALYs, Rivaroxaban was considered cost-effective at 
a conservative willingness-to-pay (WTP) level of €20,000 per 
QALY gained. Costs and health effects were not discounted 
since the time horizon of the model was limited to 1 year.
Model design
A decision-analytic model was developed in Excel 2010 to 
describe the ECV procedure, distinguishing the pre-ECV 
and post-ECV periods. A hypothetical cohort of 10,000 
patients with newly diagnosed symptomatic AF was fol-
lowed in 1-day cycles before ECV and 1-week cycles after 
ECV. The patients were scheduled for ECV when they had 
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a modified European Heart Rhythm Association (mEHRA) 
classification of 2b (moderate), 3 (severe), or 4 (disabling) 
[4]. Population characteristics and model assumptions are 
summarized in Table 1. The data used in the model were 
extracted from the literature, and access to the original data 
was not required for the analysis.
Patients who experienced an event before ECV, except 
for minor hemorrhage, and patients who were inadequately 
anticoagulated would not undergo ECV. Patients with 
inadequate anticoagulation were directly rescheduled for 
a second ECV. All patients could have an ECV procedure 
only twice within the time horizon of the model. Patients 
who experienced an event before ECV or patients with two 
unsuccessful ECV procedures were categorized as having 
“permanent AF,” and life-long rate control was initiated. 
Patients had to continue with oral anticoagulation therapy 
after ECV for 6 weeks, in accordance with the X-VeRT trial, 
irrespective of their stroke risk. After this period, men with 
a  CHA2DS2-VASc score of 1 or greater and women with 
a  CHA2DS2-VASc score of 2 or greater continued taking 
the anticoagulant they were already using (rivaroxaban or 
VKA). Patients who experienced an intracranial hemorrhage 
(ICH) discontinued anticoagulation therapy. All patients 
were assumed to start anticoagulation therapy when sched-
uled for ECV. The model outline is described in Fig. 1.
Health states and model input variables
All model input variables and their references are listed 
in Table S1. The health states included within the Markov 
model are presented in Fig. 2. A transition between these 
health states can occur at any time point, before ECV and 
after ECV, and these health states are incorporated in the 
model structure shown in Fig. 1. Spontaneous sinus rhythm 
(SSR) can occur at any time point up to the time of the ECV 
procedure. Major hemorrhage and gastrointestinal hemor-
rhage states were considered absorbing states before ECV. 
The event rates were derived from the real-world XANTUS 
study [18]. The transition probabilities were assumed to 
be equal in the rivaroxaban and VKA groups to reflect the 
minimum achievable health gains. The mortality rate for the 
simulated population was adjusted for age by our increas-
ing the age-specific mortality rate during a patient’s lifetime 
starting at 64 years [13, 19].
Health effects
Most of the baseline patient utilities for the specific events 
were calculated on the basis of EQ-5D scores for the Inter-
national Classification of Diseases ninth revision (ICD-9) 
codes. The weighted average utility for symptomatic AF was 
based on the mEHRA class 2b, 3 and 4 distribution and the 
utilities matching these classes [4]. The utility of asympto-
matic AF was the weighted average of mEHRA classes 1 and 
2a. The utility of permanent AF was the weighted average of 
all mEHRA classes, assuming that rate control would reduce 
the share of symptomatic patients. Utilities for ischemic 
stroke (IS) and ICH were based on a previously published 
nonrandomized cluster trial that explored the severity of IS 
and ICH and associated costs (see Tables S2 and S3 for the 
calculations and references). Minor hemorrhage (MiH) had 
no disutility in our model.
Table 1  Population 
characteristics of the 
hypothetical patient cohort 
and model assumptions of the 
Markov model (based on the 
X-VeRT and XANTUS trials)
CHADS2 congestive heart failure, hypertension, age 75 years or older, diabetes mellitus, prior stroke, tran-
sient ischemic attack, or thromboembolism (doubled), CHA2DS2-VASc congestive heart failure, hyperten-
sion, age 75 years or older (doubled), diabetes, prior stroke, transient ischemic attack, or thromboembolism 
(doubled), vascular disease, age 65–74 years, and sex (female), ECV electrical cardioversion, INR interna-
tional normalized ratio, NA not applicable, OAC oral anticoagulation
a Based on a time in the therapeutic range of 60%
Rivaroxaban Vitamin K antagonist Reference
Age (years) 64.4 64.4 [13]
Male sex (%) 74.0 74.0 [13]
CHADS2 score 2.0 2.0 [18]
CHA2DS2-VASc score 3.4 3.4 [18]
CHA2DS2-VASc score < 1 2.6% 2.6% [18]
CHA2DS2-VASc score < 2 12.7% 12.7% [18]
Pre-ECV OAC days 22 30 [13]
Target INR NA 2.5 (2.0–3.0) [13]
ECV success rate (%) 86.40 86.40 [13]
Inadequate OAC 1st ECV (%) 0.24 44.19 [13]
Inadequate OAC 2nd ECV (%) 0.24 20.00a [13], assumption
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Costs
All costs (in euros) were updated to the year 2015 by appli-
cation of a correction for inflation. Drug costs were based 
on total costs as presented by the Dutch Care Institute. INR 
monitoring costs were an average of the costs of home moni-
toring (43.1%) and the regular thrombosis service (56.9%). 
INR monitoring costs before cardioversion were calcu-
lated on the basis of 5.5 measurements on average before 
the ECV procedure. Periodic monitoring was on average 
21.1 and 23.5 measurements per year in patients using the 
thrombosis service or home monitoring, respectively. INR 
monitoring data were based on reports from the Federation 
of Dutch Thrombosis Services. The same underlying cal-
culation based on the severity and duration of the event as 
mentioned for the utilities was applied for the costs for the 
IS and ICH states. The cost for myocardial infarction (MI) 
is the mean weighted treatment cost for acute and postevent 
costs, with no differentiation for the type of MI and the type 
of intervention applied. Costs for minor hemorrhage were 
based on one emergency department visit, and the costs for 
major hemorrhage were based on the treatment costs for 
a gastrointestinal hemorrhage. The costs for an ECV were 
based on the average all-in declaration tariff, expert opin-
ion, and in-house experience. A “last minute” cancellation 
(canceled 48 h or less before the planned intervention) was 
Fig. 1  The decision-analytic model. Patients with a first reschedule 
could reenter (R) the model and would directly start their anticoagu-
lation period before electrical cardioversion (ECV). The red bar indi-
cates the anticoagulation period before ECV, which was different for 
the base case: 30 days for a vitamin K oral antagonist and 22 days for 
rivaroxaban. AF atrial fibrillation,  CHA2DS2-VASc congestive heart 
failure, hypertension, age 75 years or older (doubled), diabetes, prior 
stroke, transient ischemic attack, or thromboembolism (doubled), 
vascular disease, age 65–74 years, and sex (female), M1 Markov 1, 
asterisk  CHA2DS2-VASc score 1 or greater for men and 2 or greater 
for women
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calculated as half of the full tariff. The cost of cancella-
tions more than 48 h before the planned intervention was 
calculated as the administrative costs only, represented by 
30 min of work of a specialized nurse. The cost of an ECV 
cancellation because of SSR was considered as half the full 
tariff plus an extra policlinic consult with a cardiologist to 
determine the further treatment policy. Productivity loss was 
calculated into a single value based on the average popula-
tion age of 64 years (standard deviation of 10.8 years), the 
ratio of men to women, the labor market participation per 
5-year age group, the average hours of work per week per 
5-year age category, and the average monthly gross salary 
per 5-year age category. A detailed explanation of the cal-
culations can be found in Table S4. The costs of informal 
care were subdivided into “nonintensive” with 8 h of care 
provided per week and “intensive” with on average 26 h of 
care provided per week. Nonintensive informal care was 
considered for symptomatic AF patients, permanent AF 
patients, and patients who experienced a major hemorrhage 
or gastrointestinal hemorrhage. Intensive informal care was 
considered for the major events of IS, MI, and ICH during 
the remaining time horizon. The non-health care costs, both 
productivity loss and informal care costs, were applied to 
all symptomatic patients in mEHRA classes 3 and 4 during 
the remaining time horizon. The symptomatic patients in 
mEHRA classes 3 and 4 reflect 70% of all AF patients before 
ECV and 32% of all AF patients after ECV.
Sensitivity analyses
Probabilistic sensitivity analyses (PSA) were performed 
to assess the robustness of the results. The model input 
parameters were varied within their 95% confidence inter-
vals where possible, otherwise a standard error of 10–20% 
was assumed. Drug costs and indirect costs were consid-
ered at fixed prices. Event probabilities and utilities were 
assumed to have β distributions; costs were assumed to have 
γ distributions. A total of 10,000 iterations were performed 
for each combination of parameters, and the results were 
plotted in a cost-effectiveness plane. The effect of non-
health care costs was also assessed with a PSA limited to 
the health care payer perspective (i.e., omitting productiv-
ity loss costs and informal care costs). A series of univari-
ate analyses were performed to explore the effect of key 
parameter inputs by ranging them over alternative plausible 
ranges. Age, sex, and inadequate anticoagulation for VKAs 
were explored over a range of -20% to +20% of the mean 
deterministic value. To explore the effect of nonadherence to 
rivaroxaban therapy, the percentage of inadequately antico-
agulated patients before ECV in the rivaroxaban group was 
considered to be equal to the percentage in the VKA group 
(44.19%) as reported in the X-VeRT trial [13]. The effects 
of ECV costs (postponed early, postponed at the last minute, 
and postponed because of SSR) and non-health care costs 
were assessed by our taking 50% of the mean as the lower 
value and 200% of the mean as the upper value. Alternative 
treatment periods with regard to the ECV procedure were 
considered for rivaroxaban. For the lower value, a period 
of 12 days of anticoagulation before ECV was considered. 
The anticoagulation periods before ECV were assumed to be 
equal (i.e., 30 days for both a VKA and rivaroxaban) for the 
upper value. The 30-day period is also recommended in the 
AF guidelines of the European Society of Cardiology [7].
Fig. 2  The health states and transition probabilities of the decision-
analytic model. The transition probabilities before electrical cardio-
version (ECV) for the major hemorrhage (MaH) and gastrointestinal 
hemorrhage (GIH) states are different from those after ECV. Before 
ECV, MaH and GIH are absorbing states, and patients experienc-
ing one of these events are excluded from the ECV procedure [same 
representation as ischemic stroke (IS), myocardial infarction (MI), or 
intracranial hemorrhage (ICH)]. After ECV, patients will flow back to 
the atrial fibrillation (AF) state and thus can have multiple bleeding 
events. The AF state can represent asymptomatic, symptomatic, per-
manent, or recurrent AF. MiH minor hemorrhage, SSR spontaneous 
sinus rhythm
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Results
Deterministic analysis and probabilistic sensitivity 
analyses
The use of rivaroxaban as an anticoagulant in patients 
with AF scheduled for ECV would lead to a health gain of 
0.23 QALYs per patient and would cost €1.83 per patient 
with an ICER of €7.92 per QALY gained compared with 
the use of VKAs. Around 30–40% of the total cost was allo-
cated to productivity losses, and informal care costs were 
around 20% of the total cost. The total cost would be €509 
per patient, with a health gain of 0.23 QALY per patient 
from the health care payer perspective and an ICER of €2198 
per QALY gained. The results are summarized in Table 2.
The PSA from the societal perspective showed that rivar-
oxaban had a 100% probability of being cost-effective at a 
WTP level of €20,000 per QALY and would have a 49.6% 
probability of being cost-saving compared with a VKA. The 
PSA from the health care payer perspective showed that 
rivaroxaban had a 100% probability of being cost-effec-
tive and would have a 0% probability of being cost-saving 
Table 2  Health effects and total 
health care costs per patient and 
the calculated incremental cost-
effectiveness ratio (ICER) from 
the societal and health care 
payer perspectives
The ICER calculation was performed with the original, non-rounded numbers and therefore has a very 
small deviation compared to the division of the rounded incremental values
QALY quality-adjusted life year, VKA, vitamin K oral antagonist
Cost per 
patient (€)






 Rivaroxaban 4265 0.82 1.83 0.23 7.92
 VKAs 4263 0.59
Health care payer perspective
 Rivaroxaban 2475 0.82 509 0.23 2198
 VKAs 1966 0.59
Fig. 3  Incremental cost-effectiveness plane showing 10,000 Monte 
Carlo estimates of incremental health effects (quality-adjusted life 
years) and cost per patient of elective electrical cardioversion with 
rivaroxaban versus a vitamin K oral antagonist as an anticoagulant 
from the societal perspective (circles) and the health care payer per-
spective (squares)
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compared with a VKA. The PSA results from the societal 
perspective are plotted in a cost-effectiveness plane in Fig. 3.
Sensitivity analyses
The results of the sensitivity analyses are plotted in a tor-
nado diagram in Fig. 4. Varying sex (the proportion of male 
patients), the percentage of successful ECV procedures, and 
the costs of ECV had only a marginal influence on the health 
effects and costs. The success rate of ECV increased the 
incremental costs compared with the deterministic scenario 
in both the lower and the upper range. The impact of age was 
the greatest in all univariate analyses, with a higher average 
age of 77.3 years leading to an increase in costs of €360 per 
patient and a marginal QALY loss of 0.003 per patient com-
pared with an average age of 64.4 years. All other scenarios 
had a gain in QALYs, except for the univariate analysis with 
inadequate anticoagulation of 44.19% for rivaroxaban, which 
resulted in a loss of 0.0015 QALYs per patient. All results 
are summarized in Fig. 4. Equal anticoagulation periods 
for VKAs and rivaroxaban before ECV (i.e., both 30 days) 
would result in a cost increase of €246 per patient and a 
health gain of 0.24 QALYs per patient compared with VKAs 
and would still be considered cost-effective at a WTP level 
of €20,000 per QALY gained. A shorter treatment period 
would result in higher cost savings. The effect of costs due to 
productivity loss was substantial, with higher costs resulting 
in a cost-saving strategy.
Discussion
In this health economic evaluation we compared the health 
effect and economic impact of the use of rivaroxaban with 
use of a VKA before ECV. The use of rivaroxaban was 
associated with a cost of €1.83 per patient and a health 
gain of 0.23 QALYs per patient. Choosing rivaroxaban 
over a VKA would have a 49.6% probability of being cost-
saving from a societal perspective and 100% cost-effective 
at a WTP threshold of €20,000 per QALY gained. From 
the health care payer perspective, the probability of being 
cost-saving was 0%. The cost savings are mainly driven 
by the non-health care costs. The effect of costs due to 
productivity loss was larger than the effect of costs for 
informal care. Around 30–40% of the total cost was allo-
cated to productivity losses, and informal care costs were 
around 20% of the total cost. The robustness of the model 
was demonstrated in the PSA, and the influence of sev-
eral key parameters was assessed with multiple sensitivity 
analyses. The results were most sensitive to the variation 
in age, the percentage of inadequate anticoagulation, and 
costs due to productivity losses. For an equal treatment 
period before ECV but a different percentage of inadequate 
anticoagulation, rivaroxaban would still be cost-effective, 
with an ICER of €1010 per QALY gained. This health 
economic model is, to the best of our knowledge, the first 
extensive evaluation taking into account all relevant health 
effects and costs associated with the use of rivaroxaban 
versus a VKA in elective ECV. A post hoc budget-impact 
Fig. 4  Tornado diagram representing incremental total cost per patient in the univariate analyses. ECV electrical cardioversion, NOAC non-
vitamin K antagonist oral anticoagulant, OAC oral anticoagulation, VKA vitamin K oral antagonist
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analysis of the X-VeRT trial showed that the use of rivar-
oxaban in place of warfarin could result in a cost saving 
of £421 per patient in the UK and €360 per patient in Italy 
[20]. This post hoc analysis focused only on the direct 
costs associated with ECV. Patients treated with rivaroxa-
ban in the X-VeRT trial had significantly higher conveni-
ence, effectiveness, and global satisfaction scores on the 
Treatment Satisfaction Questionnaire for Medication ver-
sion II scale compared with warfarin-treated patients [20].
The effect of “in sinus rhythm” on quality of life has been 
reported in various studies, mostly based on the 36-Item 
Short Form Heath Survey (SF-36), although results are 
contradictory [5, 20]. Variables relevant to the elective 
ECV procedure and clinical outcomes were derived from 
the X-VeRT trial and XANTUS study [13, 18]. The use of 
event rates from a real-world, prospective observational 
study empowers the external validity of the health economic 
results. Transition probabilities were assumed to be equal 
for rivaroxaban and the VKA. The net clinical benefit ratio 
(the composite of stroke, non-central nervous system SE, 
transient ischemic attack, MI, cardiovascular death, and 
major bleeding) was not different between rivaroxaban and 
VKAs in the X-VeRT trial. Moreover, a subanalysis of the 
ROCKET-AF trial showed that the incidence of stroke or 
SE was not different in the rivaroxaban-treated and warfa-
rin-treated patients who underwent ECV, pharmacological 
cardioversion, or ablation [21]. The impact of the treatment 
effect is minimal with the short time horizon of the analysis, 
and therefore the assumption of equal event rates would be 
reasonable. This 1-year time horizon was chosen so as to 
focus on the ECV procedure. Using equal event rates makes 
the approach conservative and therefore represents a mini-
mum achievable health gain. We presume that the results 
will be comparable for the other NOACs since all of these 
agents have a direct effect, whereby the number of post-
ponements and/or cancellations would decrease and early 
cardioversion would be possible. The percentage of inad-
equate anticoagulation for VKAs has a large impact on the 
results, influencing the ECV procedure costs and also pro-
ductivity loss costs since patients will be in a symptomatic 
state for longer. The X-VeRT trial reported 44.2% inadequate 
anticoagulation for VKAs (target INR 2.0–3.0 maintained 
for three consecutive weeks). Although the proportion of 
inadequately anticoagulated patients seems fairly high, it 
is representative for the time in therapeutic range during 
the initiation period of VKA use. Other studies have also 
reported high, comparable proportions of inadequate anti-
coagulation before ECV, and this was the primary reason 
to postpone ECV [14–16]. Nonadherence in the post-ECV 
period was indirectly covered by use of the real-world event 
rates from the XANTUS study. These event rates reflect an 
average treatment effect based on adherent and nonadherent 
users, and therefore the health economic model developed 
and its results are a realistic representation of the real-world 
clinical setting. A 1-year time horizon was chosen in this 
analysis so as to focus on the ECV procedure and therefore 
not make it a comparison of long-term anticoagulation. The 
problem surrounding ECV is, on the one hand, the cost of 
the high number of cancellations and, on the other hand, the 
poor quality of life of symptomatic patients who have to wait 
for their ECV. Our results can support decision making by 
health care providers and payers since choosing rivaroxa-
ban over a VKA in elective ECV is cost-effective and also 
improves the planning of the procedure since (last minute) 
cancellation is less of a problem and relief of patients’ symp-
toms is accomplished earlier.
Conclusion
The use of rivaroxaban in elective ECV is considered a cost-
effective alternative to the use of VKAs at a WTP level of 
€20,000 per QALY gained. Rivaroxaban has a 50% prob-
ability of being cost-saving and would increase a patient’s 
quality of life when non-health care costs such as productiv-
ity loss and informal care costs are taken into account.
Compliance with ethical standards 
Conflict of interest MSJ and LdJ declare that they have no conflict of 
interest. MJP has received grants and honoraria from various phar-
maceutical companies, including those developing, producing, and 
marketing new oral anticoagulants. None of these grants or honoraria 
were directly related to this study. RGT has received personal fees from 
Bayer outside the submitted work. RvH has received grants from Bayer 
outside the submitted work.
Funding The authors have no financial support to declare.
Open Access This article is distributed under the terms of the Creative 
Commons Attribution 4.0 International License (http://creativecom-
mons.org/licenses/by/4.0/), which permits unrestricted use, distribu-
tion, and reproduction in any medium, provided you give appropriate 
credit to the original author(s) and the source, provide a link to the 
Creative Commons license, and indicate if changes were made.
References
 1. Heeringa, J., van der Kuip, D.A., Hofman, A., Kors, J.A., van 
Herpen, G., Stricker, B.H., Stijnen, T., Lip, G.Y., Witteman, J.C.: 
Prevalence, incidence and lifetime risk of atrial fibrillation: the 
Rotterdam study. Eur. Heart J. 27(8), 949–953 (2006)
 2. Heemstra, H.E., Nieuwlaat, R., Meijboom, M., Crijns, H.J.: The 
burden of atrial fibrillation in the Netherlands. Neth Heart J 19(9), 
373–378 (2011)
 3. Wolf, P.A., Abbott, R.D., Kannel, W.B.: Atrial fibrillation as an 
independent risk factor for stroke: the Framingham Study. Stroke 
22(8), 983–988 (1991)
965Health economic evaluation of rivaroxaban in elective cardioversion of atrial fibrillation 
1 3
 4. Wynn, G.J., Todd, D.M., Webber, M., Bonnett, L., McShane, J., 
Kirchhof, P., Gupta, D.: The European Heart Rhythm Associa-
tion symptom classification for atrial fibrillation: validation and 
improvement through a simple modification. Europace 16(7), 
965–972 (2014)
 5. Singh, S.N., Tang, X.C., Singh, B.N., Dorian, P., Reda, D.J., 
Harris, C.L., Fletcher, R.D., Sharma, S.C., Atwood, J.E., Jacob-
son, A.K., Lewis Jr., H.D., Lopez, B., Raisch, D.W., Ezekow-
itz, M.D.: Quality of life and exercise performance in patients 
in sinus rhythm versus persistent atrial fibrillation: a Veterans 
Affairs Cooperative Studies Program substudy. J. Am. Coll. Car-
diol. 48(4), 721–730 (2006)
 6. Xiong, Q., Proietti, M., Senoo, K., Lip, G.Y.: Asymptomatic ver-
sus symptomatic atrial fibrillation: a systematic review of age/
gender differences and cardiovascular outcomes. Int. J. Cardiol. 
191, 172–177 (2015)
 7. Kirchhof, P., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Cas-
adei, B., Castella, M., Diener, H.C., Heidbuchel, H., Hendriks, J., 
et al.: 2016 ESC guidelines for the management of atrial fibrilla-
tion developed in collaboration with EACTS. Eur. Heart J. 37(38), 
2893–2962 (2016)
 8. Camm, A.J., Lip, G.Y., De, Caterina R., Savelieva, I., Atar, D., 
Hohnloser, S.H., Hindricks, G., Kirchhof, P.: 2012 focused update 
of the ESC guidelines for the management of atrial fibrillation: an 
update of the 2010 ESC guidelines for the management of atrial 
fibrillation. Developed with the special contribution of the Euro-
pean Heart Rhythm Association. Eur. Heart J. 33(21), 2719–2747 
(2012)
 9. Hansen, M.L., Jepsen, R.M., Olesen, J.B., Ruwald, M.H., Kara-
soy, D., Gislason, G.H., Hansen, J., Køber, L., Husted, S., Torp-
Pedersen, C.: Thromboembolic risk in 16 274 atrial fibrillation 
patients undergoing direct current cardioversion with and without 
oral anticoagulant therapy. Europace 17(1), 18–23 (2015)
 10. Olesen, J.B., Lip, G.Y., Hansen, M.L., Hansen, P.R., Tolstrup, J.S., 
Lindhardsen, J., Selmer, C., Ahlehoff, O., Olsen, A.M., Gislason, 
G.H., Torp-Pedersen, C.: Validation of risk stratification schemes 
for predicting stroke and thromboembolism in patients with atrial 
fibrillation: nationwide cohort study. BMJ 342, d124 (2011)
 11. Banerjee, A., Lane, D.A., Torp-Pedersen, C., Lip, G.Y.: Net clini-
cal benefit of new oral anticoagulants (dabigatran, rivaroxaban, 
apixaban) versus no treatment in a ‘real world’ atrial fibrillation 
population: a modelling analysis based on a nationwide cohort 
study. Thromb. Haemost. 107(3), 584–589 (2012)
 12. Patel, M.R., Mahaffey, K.W., Garg, J., Pan, G., Singer, D.E., 
Hacke, W., Breithardt, G., Halperin, J.L., Hankey, G.J., Piccini, 
J.P., Becker, R.C., Nessel, C.C., Paolini, J.F., Berkowitz, S.D., 
Fox, K.A., Califf, R.M., ROCKET AF Steering Committee: Rivar-
oxaban versus warfarin in nonvalvular atrial fibrillation. N. Engl. 
J. Med. 365(10), 883–891 (2011)
 13. Cappato, R., Ezekowitz, M.D., Klein, A.L., Camm, A.J., Ma, 
C.S., Le, Heuzey J.Y., Talajic, M., Scanavacca, M., Vardas, P.E., 
Kirchhof, P., Hemmrich, M., Lanius, V., Meng, I.L., Wildgoose, 
P., van Eickels, M., Hohnloser, S.H.: Rivaroxaban vs. vitamin K 
antagonists for cardioversion in atrial fibrillation. Eur. Heart J. 
35(47), 3346–3355 (2014)
 14. Deuling, J.H., Vermeulen, R.P., Smit, M.D., van der Maaten, J.M., 
Boersema, H.M., van den Heuvel, A.F., Van Gelder, I.C.: Planning 
and monitoring of patients for electrical cardioversion for atrial 
fibrillation. Neth Heart J 20(4), 148–154 (2012)
 15. Kim, M.H., Krishnan, K., Jain, S., Decena, B.F.: Time course and 
frequency of subtherapeutic anticoagulation for newly prescribed 
warfarin anticoagulation before elective cardioversion of atrial 
fibrillation or flutter. Am J Cardiol 88(12), 1428–1431 (2001)
 16. Lip, G.Y., Gitt, A.K., Le, Heuzey J.Y., Bash, L.D., Morabito, C.J., 
Bernhardt, A.A., Sisk, C.M., Chazelle, F., Crijns, H.J., RHYTHM-
AF Scientific Committee: Overtreatment and undertreatment with 
anticoagulation in relation to cardioversion of atrial fibrillation (the 
RHYTHM-AF study). Am. J. Cardiol. 113(3), 480–484 (2014)
 17. Dutch Health Institute. Kostenhandleiding: methodologie van kos-
tenonderzoek en referentieprijzen voor economische evaluaties in 
de gezondheidszorg. Available at https://www.zorginstituutneder-
land.nl/over-ons/publicaties/publicatie/2016/02/29/richtlijn-voor-
hetuitvoeren-van-economische-evaluaties-in-de-gezondheidszorg 
(2015). Accessed 6 Jan 2017
 18. Camm, A.J., Amarenco, P., Haas, S., Hess, S., Kirchhof, P., Kuhls, 
S., van Eickels, M., Turpie, A.G., XANTUS Investigators: XAN-
TUS: a real-world, prospective, observational study of patients 
treated with rivaroxaban for stroke prevention in atrial fibrillation. 
Eur. Heart J. 37(14), 1145–1153 (2016)
 19. Centraal Bureau voor de Statistiek: Statline. Levensverwachting; 
geslacht, leeftijd (per jaar en periode van vijf jaren). Available at 
http://statline.cbs.nl/Statweb/publication/?DM=SLNL&PA=37
360ned&D1=0&D2=a&D3=65-99&D4=l&HDR=G1,T&STB
=G2,G3&VW=T (2016). Accessed 17 Jan 2017
 20. Hohnloser, S.H., Cappato, R., Ezekowitz, M.D., Evers, T., Sahin, 
K., Kirchhof, P., Meng, I.L., van Eickels, M., Camm, A.J.: Patient-
reported treatment satisfaction and budget impact with rivaroxaban vs. 
standard therapy in elective cardioversion of atrial fibrillation: a post 
hoc analysis of the X-VeRT trial. Europace 18(2), 184–190 (2016)
 21. Piccini, J.P., Stevens, S.R., Lokhnygina, Y., Patel, M.R., Halperin, 
J.L., Singer, D.E., Hankey, G.J., Hacke, W., Becker, R.C., Nes-
sel, C.C., Mahaffey, K.W., Fox, K.A., Califf, R.M., Breithardt, 
G., ROCKET AF Steering Committee & Investigators: Outcomes 
after cardioversion and atrial fibrillation ablation in patients 
treated with rivaroxaban and warfarin in the ROCKET AF trial. 
J. Am. Coll. Cardiol. 61(19), 1998–2006 (2013)
